NEW YORK, May 20, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Gentiva Health Services Inc. (NASDAQ: GTIV), Kindred Healthcare Inc. (NYSE: KND), Envision Healthcare Holdings, Inc. (NYSE: EVHC), Emeritus Corp. (NYSE: ESC) and Amedisys Inc. (NASDAQ: AMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2653-100free.
--
Gentiva Health Services Inc. Analyst Notes
On May 7, 2014, Gentiva Health Services Inc. (Gentiva) reported its Q1 2014 financial results with total net revenues of $487.5 million, up 17.3% YoY. Net income attributable to Gentiva shareholders were $0.3 million, or $0.01 per diluted share, compared to net loss attributable to Gentiva shareholders of $207.2 million, or $6.73 per diluted share, in Q1 2013. As of March 31, 2014, the Company reported cash and cash equivalents of $62.9 million, compared to $87.0 million at December 31, 2013. For full year 2014, the Company anticipates that net revenues will be in the range of $1.9 billion to $2.1 billion while adjusted net income attributable to Gentiva shareholders is expected to be in the range of $0.85 to $1.15 on a diluted per share basis. The full analyst notes on Gentiva are available to download free of charge at:
http://www.analystsreview.com/2653-GTIV-20May2014.pdf
--
Kindred Healthcare Inc. Analyst Notes
On May 15, 2014, Kindred Healthcare Inc. (Kindred) announced its proposal to acquire all of the outstanding shares of Gentiva Health Services, Inc. (Gentiva) common stock for a combination of $7.00 per share in cash and $7.00 of Kindred common stock. Kindred also offered to increase its offer to 100% cash if the Gentiva Board so elects. Paul J. Diaz, CEO of Kindred, said, "This compelling combination would unite two highly complementary businesses by joining Kindred's resources with Gentiva's home health and hospice capabilities. Together we would create a unique platform to 'Continue the Care' by delivering patient-centered care across the full spectrum?from hospital to outpatient facility to the patient's home." Kindred also informed that Citi is acting as financial advisor while Cleary Gottlieb Steen & Hamilton LLP is acting as legal advisor to the Company. The full analyst notes on Kindred are available to download free of charge at:
http://www.analystsreview.com/2653-KND-20May2014.pdf
--
Envision Healthcare Holdings, Inc. Analyst Notes
On May 7, 2014, Envision Healthcare Holdings, Inc. (Envision Healthcare) reported its Q1 2014 financial results with net revenue of $1.0 billion, up 14.2% YoY. Adjusted EBITDA totaled $110.0 million, up 9.0% YoY. GAAP diluted EPS was $0.13 compared to net loss per diluted share of $0.03 in Q1 2013. The Company anticipates 2014 adjusted EPS guidance in the range of $1.10 to $1.15, and adjusted EBITDA to be in the range of $538 million to $545 million. William A. Sanger, CEO, said, "We are pleased with the start of 2014 and our industry leading organic growth." He continued, "We believe the momentum in our businesses, combined with the impact of the ACA, has created a strong foundation for future growth." The full analyst notes on Envision Healthcare are available to download free of charge at:
http://www.analystsreview.com/2653-EVHC-20May2014.pdf
--
Emeritus Corp. Analyst Notes
On May 8, 2014, Emeritus Corp. (Emeritus) reported its Q1 2014 financial results with net loss of $49.0 million compared to $39.7 million in Q1 2013. Total operating revenues were $521.8 million, a growth of 10.5% YoY. Adjusted EBITDA for the quarter totaled $93.4 million compared to $93.0 million in Q1 2013. Granger Cobb, President and CEO, commented, "Our intense focus on service and customer satisfaction yielded significant results - overcoming historical seasonal softness, we produced a 30-basis-point sequential improvement in Total Portfolio Same Community occupancy from the fourth quarter, and an 80-basis-point improvement over the first quarter of last year. Our performance is a tribute to our 32,000 extremely dedicated Emeritus employees who, amidst potential transaction distraction, remain resolutely focused on providing a fulfilling customer experience for our residents and peace of mind for their families." The full analyst notes on Emeritus are available to download free of charge at:
http://www.analystsreview.com/2653-ESC-20May2014.pdf
--
Amedisys Inc. Analyst Notes
On May 8, 2014, Amedisys Inc. (Amedisys) reported its unaudited Q1 2014 financial results with net service revenue of $298.7 million compared to $328.6 million in Q1 2013. Net loss from continuing operations attributable to Amedisys was $2.2 million or $0.07 per diluted share, compared to net income from continuing operations of $4.7 million or $0.15 per diluted share in Q1 2013. Ronald A. LaBorde, Interim CEO commented, "We are extremely proud of our dedicated teams in the field that provide care for over 60,000 patients every day. Their consistent efforts continue to yield improvement in clinical outcomes. Where we have fallen short is translating that clinical focus to consistent operating results. Our efforts are focused on turning that around." The full analyst notes on Amedisys are available to download free of charge at:
http://www.analystsreview.com/2653-AMED-20May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
